Lung cancer is a major global health problem, as it is the leading cause of cancer-related
deaths worldwide. Major advances in the identification of key mutational alterations have led …

Brain metastases (BrM) are common in both non–small-cell lung cancer and small-cell lung
cancer. Substantial progress in BrM management has occurred in the past decade related to …

Background Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK),
has antitumor activity in previously treated patients with ALK-positive non–small-cell lung …

Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …

Introduction This exploratory analysis retrospectively evaluated outcomes in patients with
advanced NSCLC to determine whether baseline brain metastases influenced the efficacy of …

Introduction Metastatic spread to the brain is common in patients with non–small cell lung
cancer (NSCLC), but these patients are generally excluded from prospective clinical trials …

Smoking is associated with lung cancer and has a profound impact on tumor immunity.
Nicotine, the addictive and non-carcinogenic smoke component, influences various brain …

Background Lung cancer is the most common and deadliest cancer worldwide, and
approximately 90% of all lung cancer deaths are caused by tumor metastasis. Tumor …

Purpose: Primary analysis of VISION showed tepotinib had durable clinical activity in
patients with MET exon 14 (MET ex14) skipping non–small cell lung cancer (NSCLC). We …

Up to 40% of lung cancer patients develop brain metastasis, and the median survival of
these patients remains less than 6 months. Smoking is associated with lung cancer …